Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2022; 12(03): 154-156
DOI: 10.1055/s-0042-1750716
Case Report

Acute Liver Injury due to Glecaprevir/Pibrentasvir in a Patient with Chronic Hepatitis C Virus Infection without Cirrhosis

Ayushi Jain 
1   Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
,
Khalid Mumtaz
2   Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

We reported a rare case of acute liver injury in a patient with chronic hepatitis C virus infection without cirrhosis 4 weeks after initiation of glecaprevir/pibrentasvir. After prompt cessation of antiviral therapy, liver enzymes rapidly improved toward baseline. This case reflects the need to remain vigilant for the development of acute liver injury after initiation of glecaprevir/pibrentasvir even without a diagnosis of cirrhosis.

Keywords

acute liver injury - drug induced liver injury - hepatitis C - glecaprevir/pibrentasvir

Note

Informed consent was obtained for this case report.


Authors' Contributions

A.J. and K.M. wrote the manuscript. K.M. is the article guarantor.




Publication History

Article published online:
03 July 2022

© 2022. Avicenna Journal of Medicine. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Müllhaupt B, Semela D, Ruckstuhl L. et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. Swiss Med Wkly 2021; 151: w20399
    CrossrefPubMedGoogle Scholar
  • 2 FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. U.S. Food and Drug Administration; 2019
    PubMedGoogle Scholar
  • 3 Yoon JH, Kim SM, Kang G, Kim HJ, Jun CH, Choi SK. A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis. Medicine (Baltimore) 2019; 98 (39) e17343
    CrossrefPubMedGoogle Scholar
  • 4 Naranjo CA, Busto U, Sellers EM. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (02) 239-245
    CrossrefPubMedGoogle Scholar
  • 5 Highlights of Prescribing Information. FDA. 2017 . Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208434s003lbl.pdf
    PubMedGoogle Scholar
  • 6 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guidelines Panel: Chair, EASL Governing Board representative, Panel members. EASL recommendations on treatment of hepatitis C: final update of the series☆. J Hepatol 2020; 73 (05) 1170-1218
    CrossrefPubMedGoogle Scholar
  • 7 Hammami MB, Aboushaar R, Alsabbagh E. Glecaprevir/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection. BMJ Case Rep 2019; 12 (05) e226622
    CrossrefPubMedGoogle Scholar
  • 8 Hara T, Ohara T, Taniguchi M. et al. Severe liver injury associated with glecaprevir plus pibrentasvir therapy in a patient with treatment-naïve hepatitis C virus infection. Intern Med 2021; 60 (15) 2437-2443
    CrossrefPubMedGoogle Scholar
  • 9 Mavyret, in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012
    Google Scholar